ArticleNature microbiology2026
Pooled CRISPRi screening reveals fungal-specific drug target candidates.
Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathogenicity and virulence ofVirulence · 2026Review
- CRISPR-activation reveals key resistance genes and vulnerabilities of copy number variants inbioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
The rising rate of drug-resistant fungal infections and the emergence of intrinsically resistant pathogens pose growing clinical challenges. Because fungi are closely related to mammals, developing antifungals without toxic off-target effects is difficult. Targeted gene repression can model drug-mediated inhibition and reveal gene dosage sensitivity, but traditional approaches in the fungal pathogen Candida albicans are labour intensive and low throughput. Here we adapt pooled CRISPR interference (CRISPRi) screening in C. albicans to enable large-scale functional genomic analysis. We assess repression sensitivity of 130 essential genes conserved in fungi without close homologues in humans and identify highly dosage-sensitive genes across multiple pathways. Screening across ten environmental conditions reveals environment-dependent effects on gene sensitivity. Extending these experiments to two drug-resistant clinical isolates shows that many fitness defects are conserved across genetic backgrounds. Thus, CRISPRi pooled screening enables rapid, large-scale functional genomics across diverse genetic backgrounds in C. albicans.
Indexed as
Identifiers
42115739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.